Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNC Centene	$54.48 -1.2%	$58.49	$53.99 ▼ $80.59	$27.44B	0.45	4.94 million shs	11.16 million shs
HUM Humana	$239.66 -1.5%	$245.76	$212.45 ▼ $406.46	$29.38B	0.43	1.81 million shs	2.05 million shs
MCK McKesson	$720.88 -1.1%	$708.42	$464.42 ▼ $733.10	$91.20B	0.49	924,030 shs	1.37 million shs
TAK Takeda Pharmaceutical	$14.75 -1.0%	$14.79	$12.60 ▼ $15.43	$47.41B	0.23	1.95 million shs	3.41 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNC Centene	-1.09%	-1.29%	-10.32%	-7.47%	-17.93%
HUM Humana	-1.62%	+2.04%	-2.59%	-10.01%	-31.44%
MCK McKesson	-1.15%	-0.86%	+0.41%	+9.31%	+19.56%
TAK Takeda Pharmaceutical	-1.07%	-2.99%	+2.93%	-2.96%	+16.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNC Centene	4.9674 of 5 stars	4.3	5.0	0.0	3.6	2.0	1.7	3.8
HUM Humana	4.4418 of 5 stars	3.2	3.0	2.5	3.9	1.9	1.7	1.3
MCK McKesson	4.3948 of 5 stars	2.4	3.0	3.3	3.0	2.9	2.5	1.3
TAK Takeda Pharmaceutical	0.7756 of 5 stars	0.0	3.0	1.7	0.0	1.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNC Centene	2.56	Moderate Buy	$77.71	42.64% Upside
HUM Humana	2.30	Hold	$280.76	17.15% Upside
MCK McKesson	2.87	Moderate Buy	$694.38	-3.67% Downside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest HUM, CNC, MCK, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	HUM Humana	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$320.00 ➝ $260.00
6/17/2025	HUM Humana	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$305.00 ➝ $280.00
6/12/2025	HUM Humana	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$273.00 ➝ $268.00
6/11/2025	MCK McKesson	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$745.00 ➝ $770.00
6/9/2025	CNC Centene	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
6/3/2025	MCK McKesson	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$691.00 ➝ $766.00
6/2/2025	CNC Centene	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$84.00 ➝ $65.00
6/2/2025	HUM Humana	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$322.00 ➝ $273.00
5/12/2025	HUM Humana	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$325.00 ➝ $305.00
5/9/2025	MCK McKesson	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$755.00 ➝ $800.00
5/1/2025	HUM Humana	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$290.00 ➝ $290.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNC Centene	$169.28B	0.16	$9.78 per share	5.57	$52.49 per share	1.04
HUM Humana	$117.76B	0.25	$23.50 per share	10.20	$136.57 per share	1.75
MCK McKesson	$359.05B	0.25	$38.43 per share	18.76	($13.52) per share	-53.32
TAK Takeda Pharmaceutical	$30.09B	1.56	$3.14 per share	4.69	$14.39 per share	1.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNC Centene	$3.31B	$6.71	8.12	7.39	0.66	2.04%	14.56%	4.75%	7/25/2025 (Estimated)
HUM Humana	$1.21B	$14.14	16.95	18.25	1.84	1.42%	14.47%	5.03%	7/30/2025 (Estimated)
MCK McKesson	$3.30B	$25.83	27.91	19.67	1.46	0.92%	-201.12%	5.83%	8/6/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	67.03	8.94	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)

Latest HUM, CNC, MCK, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q4 2025	MCK McKesson	$9.83	$10.12	+$0.29	$10.01	$94.00 billion	$90.82 billion
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
4/30/2025	Q1 2025	HUM Humana	$10.07	$11.58	+$1.51	$10.30	$32.00 billion	$32.11 billion
4/25/2025	Q1 2025	CNC Centene	$2.52	$2.90	+$0.38	$2.63	$43.16 billion	$46.62 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNC Centene	N/A	N/A	N/A	N/A	N/A
HUM Humana	$3.54	1.48%	N/A	25.04%	N/A
MCK McKesson	$2.84	0.39%	N/A	10.99%	17 Years
TAK Takeda Pharmaceutical	$0.27	1.83%	N/A	122.73%	N/A

Latest HUM, CNC, MCK, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/17/2025	HUM Humana	quarterly	$0.8850	1.24%	6/27/2025	6/27/2025	7/25/2025
5/1/2025	MCK McKesson	quarterly	$0.71	0.4%	6/2/2025	6/2/2025	7/1/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNC Centene	0.65	1.11	1.11
HUM Humana	0.71	1.91	1.91
MCK McKesson	N/A	0.90	0.53
TAK Takeda Pharmaceutical	0.57	1.01	0.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNC Centene	93.63%
HUM Humana	92.38%
MCK McKesson	85.07%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
CNC Centene	0.36%
HUM Humana	0.37%
MCK McKesson	0.11%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNC Centene	60,500	497.60 million	495.81 million	Optionable
HUM Humana	65,680	120.69 million	120.25 million	Optionable
MCK McKesson	45,000	125.11 million	124.97 million	Optionable
TAK Takeda Pharmaceutical	49,281	3.18 billion	3.18 billion	Optionable

HUM, CNC, MCK, and TAK Headlines

Recent News About These Companies

Inscription Capital LLC Invests $303,000 in Takeda Pharmaceutical Co. (NYSE:TAK)

June 19 at 4:21 AM | marketbeat.com

Wisner Baum: Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly

June 18 at 9:33 PM | kxan.com

Takeda Pharmaceutical Co. (NYSE:TAK) Shares Purchased by QRG Capital Management Inc.

June 18 at 4:23 AM | marketbeat.com

Trump rekindles pharmaceutical tariff threat, suggesting import duties could come 'very soon': Reuters

June 17, 2025 | fiercepharma.com

Class Status Upheld in Takeda, Eli Lilly RICO Suit Over Actos

June 17, 2025 | news.bloomberglaw.com

GAMMA Investing LLC Has $1.56 Million Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 15, 2025 | marketbeat.com

Sun Pharma announce major leadership shake-up, names Kirti Ganorkar as MD, Shanghvi steps into executive Chairman Role

June 14, 2025 | moneycontrol.com

Sun Pharma names Kirti Ganorkar as new managing director, Dilip Shanghvi to continue as chairman

June 13, 2025 | msn.com

Wealth Enhancement Advisory Services LLC Lowers Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 9, 2025 | marketbeat.com

Clean Yield Group Lowers Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 8, 2025 | marketbeat.com

Takeda CEO Christophe Weber faces opposition to board reelection

June 7, 2025 | asia.nikkei.com

Itochu working to support overseas pharma firms to fill Japan's drug gaps

June 4, 2025 | japantimes.co.jp

Takeda Reports Adcetris Combo Approved by EC for Hodgkin Lymphoma

June 4, 2025 | msn.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Bought by NBC Securities Inc.

June 4, 2025 | marketbeat.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Up 33.3% in May

June 3, 2025 | marketbeat.com

Medicamen Biotech rallies after securing USFDA approval for Bortezomib injection

June 3, 2025 | business-standard.com

Rusfertide reduces blood draws, maintains hematocrit, eases symptoms in polycythemia vera

June 2, 2025 | healio.com

ASCO: Takeda and Protagonist release positive Phase III VERIFY study of rusfertide in polycythemia vera

June 2, 2025 | thepharmaletter.com

Legacy Wealth Asset Management LLC Buys 44,635 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 2, 2025 | marketbeat.com

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

June 1, 2025 | businesswire.com

Versant Capital Management Inc Purchases 23,166 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HUM, CNC, MCK, and TAK Company Descriptions

Centene NYSE:CNC

$54.48 -0.67 (-1.21%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$54.44 -0.05 (-0.09%)

As of 06/20/2025 07:59 PM Eastern

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental and speech therapy services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri.

Humana NYSE:HUM

$239.66 -3.74 (-1.54%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$240.25 +0.59 (+0.25%)

As of 06/20/2025 07:56 PM Eastern

Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of pharmacy benefit manager business. Further, it operates pharmacies and senior focused primary care centers; and offers home solutions services, such as home health, hospice, and other services to its health plan members, as well as to third parties. The company sells its products through employers and employees, independent brokers and agents, sales representatives, and digital insurance agencies. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

McKesson NYSE:MCK

$720.88 -8.03 (-1.10%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$728.56 +7.68 (+1.07%)

As of 06/20/2025 07:57 PM Eastern

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners, and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Takeda Pharmaceutical NYSE:TAK

$14.74 -0.16 (-1.04%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$15.13 +0.39 (+2.64%)

As of 06/20/2025 06:57 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time